1. Home
  2. ELVN

as 11-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

Founded: 2016 Country:
United States
United States
Employees: N/A City: BOULDER
Market Cap: 1.3B IPO Year: 2020
Target Price: $34.75 AVG Volume (30 days): 232.2K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.92 EPS Growth: N/A
52 Week Low/High: $9.80 - $30.03 Next Earning Date: 11-19-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

ELVN Daily Stock ML Predictions

Stock Insider Trading Activity of Enliven Therapeutics Inc. (ELVN)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Lyssikatos Joseph P ELVN CHIEF SCIENTIFIC OFFICER Oct 18 '24 Sell $30.00 847 $25,412.54 1,015,188
Collins Helen Louise ELVN CHIEF MEDICAL OFFICER Oct 18 '24 Sell $30.00 816 $24,482.45 0
Kintz Samuel ELVN PRESIDENT AND CEO Oct 18 '24 Sell $30.00 924 $27,722.68 1,002,892
Heyman Richard A. ELVN Director Oct 15 '24 Sell $27.67 1,270 $35,143.31 124,490
Ballal Rahul D. ELVN Director Oct 8 '24 Sell $28.17 10,420 $293,557.45 22,341
Lyssikatos Joseph P ELVN CHIEF SCIENTIFIC OFFICER Oct 4 '24 Sell $27.56 10,229 $281,664.00 1,015,188
Hohl Benjamin ELVN CHIEF FINANCIAL OFFICER Oct 4 '24 Sell $27.51 11,488 $316,014.07 0
Kintz Samuel ELVN PRESIDENT AND CEO Oct 4 '24 Sell $27.51 14,936 $410,866.94 1,002,892
Lyssikatos Joseph P ELVN CHIEF SCIENTIFIC OFFICER Oct 1 '24 Sell $27.54 527 $14,512.10 1,015,188
Heyman Richard A. ELVN Director Oct 1 '24 Sell $27.54 518 $14,264.32 124,490

Share on Social Networks: